TheraRadar
Data updated: May 26, 2026

AVZIVI (bevacizumab-tnjn)

Oncology Approved 2023-12-06

AVZIVI is indicated for the treatment of Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.

Source: FDA Label • BIO-THERA SOLUTIONS LTD
1
Indication
--
Phase 3 Trials
2
Years on Market

Details

Status
Prescription
First Approved
2023-12-06
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: BEVACIZUMAB-TNJN

AVZIVI Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2023 to 2023
Dec 2023 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What AVZIVI Treats

8 indications

AVZIVI is approved for 8 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Metastatic Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Glioblastoma
  • Renal Cell Carcinoma
  • Cervical Cancer
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
Source: FDA Label
Biosimilar for Avastin

AVZIVI is a lower-cost alternative to Avastin with no clinically meaningful differences. Requires prescriber approval to substitute.

AVZIVI Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to AVZIVI

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

MVASI
BEVACIZUMAB-AWWB
7 shared
Amgen
ZIRABEV
BEVACIZUMAB-BVZR
7 shared
Pfizer
JOBEVNE
BEVACIZUMAB-NWGD
6 shared
BIOCON BIOLOGICS INC
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AVZIVI FDA Label Details

Indications & Usage

FDA Label (PDF)

AVZIVI is indicated for the treatment of Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer.

Track AVZIVI with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.